Quantitative Determination of Nitrendipine in Human Plasma Using High-performance Liquid Chromatography-Mass Spectrometry

Abstract

A sensitive and highly selective liquid chromatography-mass spectrometry (LC-MS) method was developed to determine nitrendipine (4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3, 5-pyridinedicarboxylic acid ethyl methyl ester, CAS 39562-70-4) in human plasma. The analyte and the internal standard nimodipine (CAS 66085-59-4) were extracted from plasma samples by n-hexane-isopropanol (95:5, v/v), and analyzed on a commercially available column interfaced with a mass spectrometer. Positive atmospheric pressure chemical ionization (APCI) was empolyed as the ionization source. The samples were detected by the use of selected ion monitoring (SIM) mode. The mobile phase consisted of methanol-water (75:25, v/v). The method has a limit of detection (LOD) of 0.1 ng/ml. The linear calibration curves were obtained in the concentrations range of 0.3–40 ng/ml (r²≥0.99). The intra- and inter-day batch precisions were lower than 10% in terms of relative standard deviation (R. S. D.), and the accuracy ranged from 85 to 110% in terms of percent accuracy. The overall extraction recoveries were determined to be about 75% on average. This validated method was successfully applied to the evaluation of the pharmacokinetic profiles of nitrendipine tablets administered to 8 Chinese healthy volunteers.

Key words

Calcium antagonists, 1,4-dihydropyridine - CAS 39562-70-4 - Nitrendipine, bioavailability, LC-MS method, pharmacokinetics

• Literature

• 1 Beck O, Ryman T. Quantification of nitrendipine in plasma by a capillary column gas chromatographic – mass spectrometric method. J Chromatogr. 1985; 337: 402-408
• 2 Pastera J, Mejstrikova L, Zoulova J, Macek K, Kvetina J. Simultaneous determination of nitrendipine and one of its metabolites in plasma samples by gas chromatography with electron-capture detection. J Pharm Biomed Anal. 2006; 18: 279-284
• 3 Soons PA, Breimer DD. Gas chromatographic analysis of nitrendipine and its pyridine metabolite in human plasma. J Chromatogr. 1988; 428: 362-367
• 4 Venishetty VK, Durairaj C, Sistla R, Yamsani MR, Diwan PV. Development and validation of a reversed-phase HPLC method for determination of nitrendipine in rat plasma: application to pharmacokinetic studies. Biomed Chromatogr. 2007; 21: 363-368
• 5 Soo YO, Kwang YK, Yoon GK, Hyung-Gun Kim. High-performance liquid chromatographic analysis of nitrendipine in human plasma using ultraviolet detection and single-step solid-phase sample preparation. J Pharm Biomed Anal. 2003; 32: 387-392
• 6 Marinkovic V, Agbaba D, Vladimirov S, Stankovic S. Simultaneous HPLC determination of nitrendipine and impurities of the process of synthesis. J Pharm Biomed Anal. 2001; 24: 993-998
• 7 Baranda AB, Jiménez RM, Alonso RM. Simultaneous determination of five 1,4-dihydropyridines in pharmaceutical formulations by high-performance liquid chromatographyamperometric detection. J Chromatogr A. 2004; 1031: 275-280
• 8 Chen XY, Zhong DF, Yang HY, Luan Y, Xu HY. Quantitative determination of nitrendipine and its metabolite dehydronitrendipine in human plasma using liquid chromatographytandem mass spectrometry. Biomed Chromatogr. 2001; 15: 518-524
• 9 Baranda AB, Mueller CA, Alonso RM, Jimenez RM, Weinmann W. Quantitative determination of the calcium channel antagonists amlodipine, lercanidipine, nitrendipine, felodipine, and lacidipine in human plasma using liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2005; 27: 44-52